Novel PABA-based compounds exhibit antimicrobial activity against resistant strains, indicating potential therapeutic applications.
Novel PABA-based hybrids were developed as dual DHPS/DHFR inhibitors, showing promising antimicrobial activity against resistant strains supported by experimental and computational studies.
No takes yet. Share an insight, caveat, or question.
Devliya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: